As of 2026-03-14, the EV/EBITDA ratio of Enanta Pharmaceuticals Inc (ENTA) is -6.86. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. ENTA's latest enterprise value is 467.23 mil USD. ENTA's TTM EBITDA according to its financial statements is -68.13 mil USD. Dividing these 2 quantities gives us the above ENTA EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 8.5x - 14.3x | 12.0x |
| Forward P/E multiples | 10.6x - 19.2x | 14.7x |
| Fair Price | (28.29) - (37.07) | (34.74) |
| Upside | -322.7% - -391.9% | -373.6% |
| Date | EV/EBITDA |
| 2026-03-13 | -6.86 |
| 2026-03-12 | -7.16 |
| 2026-03-11 | -7.48 |
| 2026-03-10 | -7.39 |
| 2026-03-09 | -7.36 |
| 2026-03-06 | -7.22 |
| 2026-03-05 | -7.30 |
| 2026-03-04 | -8.01 |
| 2026-03-03 | -7.72 |
| 2026-03-02 | -7.63 |
| 2026-02-27 | -7.54 |
| 2026-02-26 | -7.59 |
| 2026-02-25 | -7.68 |
| 2026-02-24 | -7.73 |
| 2026-02-23 | -7.19 |
| 2026-02-20 | -7.20 |
| 2026-02-19 | -7.41 |
| 2026-02-18 | -7.36 |
| 2026-02-17 | -7.35 |
| 2026-02-13 | -7.35 |
| 2026-02-12 | -7.34 |
| 2026-02-11 | -7.52 |
| 2026-02-10 | -7.47 |
| 2026-02-09 | -7.34 |
| 2026-02-06 | -7.20 |
| 2026-02-05 | -6.97 |
| 2026-02-04 | -7.19 |
| 2026-02-03 | -7.23 |
| 2026-02-02 | -7.07 |
| 2026-01-30 | -6.94 |
| 2026-01-29 | -6.94 |
| 2026-01-28 | -6.84 |
| 2026-01-27 | -6.98 |
| 2026-01-26 | -6.95 |
| 2026-01-23 | -6.99 |
| 2026-01-22 | -6.90 |
| 2026-01-21 | -6.80 |
| 2026-01-20 | -6.77 |
| 2026-01-16 | -6.82 |
| 2026-01-15 | -7.13 |
| 2026-01-14 | -7.34 |
| 2026-01-13 | -7.04 |
| 2026-01-12 | -6.95 |
| 2026-01-09 | -7.03 |
| 2026-01-08 | -7.17 |
| 2026-01-07 | -7.36 |
| 2026-01-06 | -7.23 |
| 2026-01-05 | -7.37 |
| 2026-01-02 | -7.59 |
| 2025-12-31 | -8.17 |